For lung cancer, many studies have demonstrated that using siRNA to suppress STAT3 expression could successfully repress cancer development, reverse drug resistance (chemotherapeutic drugs and TKIs), and improve immunotherapy by inhibiting proliferation, migration, and ROS production of cancer cells as well as decreasing the expression of PD-L1 on immune cells [60,61,62]. This evidence concerns the gene STAT3 and lung carcinoma.